Want to see EDSA full AI Analyst Report?
EDSA Stock Chart & Stats
$1.48
>-$0.01(-0.02%)
At close: 4:00 PM EST
$1.48
>-$0.01(-0.02%)
Day’s Range― - ―
52-Week Range$0.72 - $20.32
Previous CloseN/A
Volume1.31K
Average Volume (3M)151.13K
Market Cap
$63.58M
Enterprise Value$43.04
Total Cash (Recent Filing)$10.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.51
Next Earnings
Aug 07, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding9,633,223
10 Day Avg. Volume51,262
30 Day Avg. Volume151,127
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.13
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$21.00Price Target Upside1318.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.87
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthEdesa’s minimal debt and roughly $12.4M of equity provide a durable solvency cushion versus highly leveraged peers. Low financial leverage preserves access to capital markets and strategic optionality to fund trials or partner deals, moderating the binary risk profile of a clinical-stage biotech.
Insider-Led PIPE FinancingThe ~$3.5M PIPE led by the CEO and sector investors meaningfully extends runway for core programs. Insider participation signals management conviction and specialist backing, improving prospects for executing key clinical milestones and making near-term program continuity less dependent on unsecured market access.
Exploratory Clinical Signal (paridiprubart)Reported reductions in mortality and improved kidney outcomes for paridiprubart suggest a biologically plausible, multi-organ impact of TLR4 inhibition. Even as exploratory findings, they provide a durable development rationale and inform trial design and potential label expansion paths if confirmed in prospective studies.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow (~-$7.6M TTM) is intrinsic to development-stage biotechs and requires repeated capital raises. Over months, persistent burn increases financing dependency, constrains discretionary R&D spend, and raises execution risk if capital markets tighten or trial timelines slip.
No Commercial Revenue / Large LossesWith negligible product revenue (~$50.9K TTM) and a ~-$10.4M net loss, operational sustainability hinges on clinical success and external financing. Absence of recurring revenue means the company’s long-term viability is tied to milestone/partnering outcomes rather than business-model cash generation.
Dilution Risk From Equity Compensation And Plan ExpansionApproval to expand the equity incentive pool plus a shift to 90% of CEO pay in vested RSUs materially raises potential share issuance. While conserving cash, this structural change increases dilution risk and could erode per-share economics over time if used broadly for compensation or financing.
Edesa Biotech News
EDSA FAQ
What was Edesa Biotech’s price range in the past 12 months?
Edesa Biotech lowest stock price was $0.72 and its highest was $20.32 in the past 12 months.
What is Edesa Biotech’s market cap?
Edesa Biotech’s market cap is $63.58M.
When is Edesa Biotech’s upcoming earnings report date?
Edesa Biotech’s upcoming earnings report date is Aug 07, 2026 which is in 17 days.
How were Edesa Biotech’s earnings last quarter?
Edesa Biotech released its earnings results on May 14, 2026. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.26 by -$0.23.
Is Edesa Biotech overvalued?
According to Wall Street analysts Edesa Biotech’s price is currently Undervalued.
Does Edesa Biotech pay dividends?
Edesa Biotech does not currently pay dividends.
What is Edesa Biotech’s EPS estimate?
Edesa Biotech’s EPS estimate is -0.44.
How many shares outstanding does Edesa Biotech have?
Edesa Biotech has 9,633,223 shares outstanding.
What happened to Edesa Biotech’s price movement after its last earnings report?
Edesa Biotech reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.26. Following the earnings report the stock price went down -10.678%.
Which hedge fund is a major shareholder of Edesa Biotech?
Currently, no hedge funds are holding shares in EDSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edesa Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.00 (1318.92% Upside)
$21.00 (1318.92% Upside)
Blogger Sentiment
Bullish
EDSA Sentiment 70%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
178.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-24.73%
Trailing 12-Months
Company Description
Edesa Biotech
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
EDSA Stock 12 Month Forecast
Average Price Target
$21.00
▲(1318.92% Upside)
Technical Analysis
Eterna Therapeutics
―
Lipocine
―
XTL Biopharmaceuticals Sponsored ADR
―
Cocrystal Pharma
―
BioVie
―
Ownership Overview
21.56% Insiders
1.30% Mutual Funds
22.38% Other Institutional Investors
53.91% Public Companies and
Individual Investors